

# Congress of the United States

Washington, DC 20515

June 29, 2026

The Honorable Robert F. Kennedy, Jr.  
Secretary  
U.S. Department of Health and Human  
Services  
200 Independence Avenue, SW  
Washington, DC 20201

The Honorable Thomas J. Engels  
Administrator  
Health Resources and Services  
Administration  
U.S. Department of Health and Human  
Services  
5600 Fishers Lane  
Rockville, MD 20857

Dear Secretary Kennedy and Administrator Engels:

We write to express our serious concern regarding the recent action by Eli Lilly and Company (Lilly) terminating 340B pricing for covered entities' (CE) that do not comply with its in-house claims data policy. We urge the Department of Health and Human Services (HHS) and the Health Resources and Services Administration (HRSA) to take immediate action that will ensure Lilly's compliance with its pricing obligations under the 340B statute and reinstate 340B pricing for all CEs impacted.

As you are aware, Lilly and a growing number of other pharmaceutical companies have announced policies that threaten to bar access to 340B discount pricing for their drugs unless the CE shares claims-level data from in-house pharmacies, including from mixed-use pharmacies for drugs administered in the hospital to outpatients. Lilly notified some CEs that it planned to tell wholesalers within five business days of June 1, 2026, that those CEs were no longer eligible for 340B pricing unless the CEs acceded to Lilly's data demands. On June 18, 2026, Lilly terminated access to 340B pricing for select hospitals, forcing those hospitals to either purchase Lilly drugs at their high list prices or accede to Lilly's data demands. Lilly notified HRSA of its plans to send similar letters to additional CEs in the coming months. All the while, these CE's eligibility for the program has not changed, only Lilly's demands.

Congress established 340B to enable safety-net providers to stretch scarce federal resources, expand access to care, and furnish more comprehensive services to vulnerable patients. The statute requires participating drug manufacturers to offer covered outpatient drugs to eligible covered entities at or below the statutory ceiling price as a condition of their participation in the Medicare and Medicaid programs. Congress did not authorize manufacturers to unilaterally impose additional reporting mandates or data-sharing requirements as a prerequisite for obtaining those discounts.

Lilly's actions effectively condition participation in the 340B program on compliance with manufacturer-imposed requirements that extend beyond the statutory framework established by Congress. Such actions create significant administrative and operational burdens for covered entities, requiring hospitals, health centers, and clinics to devote substantial resources toward

collecting, validating, and transmitting claims information rather than providing patient care. We believe this to be in direct opposition to the intention of the program.

Even more troubling, the suspension of 340B pricing will have immediate and far-reaching consequences for safety-net providers and the patients they serve. Many covered entities rely on 340B savings to support uncompensated care, rural health services, oncology programs, behavioral health treatment, pharmacy services, and other essential programs that would otherwise be difficult to sustain. Disruption to their access to 340B pricing threatens the financial stability of these providers and undermines access to care for underserved communities.

An additional issue with this move is the pretext upon which Lilly is predicating its push for claims data submissions. Lilly, along with other drug manufacturers currently engaged in this same pursuit, is arguing that recent court decisions in the U.S. Court of Appeals for the Third and D.C. Circuits give them the authority to demand access to medical claims data from covered entities as a condition for 340B discount pricing.<sup>1,2</sup> Their interpretation of these court decisions is an inaccurate reading of what these circuit courts found in their rulings. The decisions in these cases only apply to contract pharmacy claims because the 340B statute does not explicitly cover the issue of contract pharmacy; they do not apply to the in-house pharmacy claims that Lilly is demanding through its threats to cut off 340B pricing. Even within the context of its specific ruling on contract pharmacy, the D.C. Circuit decision specifically acknowledged that while some restrictions on 340B could be considered lawful, it is also possible that some could be so onerous and restrictive toward covered entities' continued participation in the program that they would be unlawful as a result. The push for in-house pharmacy claims data submission would qualify as especially onerous and restrictive.

Lilly also refers to the claims-level data that it is requiring under its in-house policy as “standard information” that covered entities already transmit to others, including payers, relying on guidance published by HRSA in 1994 to support its ability to “request standard information” from covered entities as a “condition” of 340B pricing.<sup>3,4</sup> 340B hospitals have never routinely submitted to manufacturers the set of claims-level information Lilly demands. Lilly alleges in its letter to HRSA that 70% of covered entities purchasing Lilly medications, or 2,350 entities, are submitting data to Lilly. There are 12,585 covered entities registered in the states that are not exempt from Lilly's policy due to state 340B laws.<sup>5</sup> If only 2,350 of those entities are submitting data, that means that more than 80% of covered entities in the applicable states are not providing data, demonstrating that Lilly's data requirements are not customary.

The 1994 guidance clearly states that manufacturers may not “single out covered entities” for “restrictive conditions that would undermine the [340B] statutory objective,” but “may include provisions in their contracts with covered entities that address customary business practice, request standard information, or include other appropriate contract provisions.”<sup>6</sup> The guidance also explicitly prohibits manufacturers from requiring CEs to provide assurances that they comply with 340B provisions as a condition of receiving 340B pricing.<sup>7</sup> The guidance does not

1. Novartis Pharmaceuticals Corp. v. Johnson (formerly Novartis Pharmaceuticals Corp. v. Becerra) No. 21-5299, U.S. Court of Appeals for the D.C. Circuit. <https://law.justia.com/cases/federal/appellate-courts/cadc/21-5299/21-5299-2024-05-21.html>

2. Sanofi Aventis U.S. LLC v. U.S. Department of Health & Human Services, No. 21-3167, U.S. Court of Appeals for the Third Circuit. <https://www2.ca3.uscourts.gov/opinarch/213167p.pdf>

3. Letter from Eli Lilly and Co. to Thomas J. Engels, Adm'r, Health Res. & Servs. Admin. (June 1, 2026), <https://www.lilly.com/news/stories/lilly-in-house-claims-data-requirement-upcoming-action>.

4. *Id.* Footnotes 2, 5.

5. HRSA Office of Pharmacy Affairs, 340B OPAIS, “Covered Entities”, <https://340bopais.hrsa.gov/SearchCe>

6. 59 Fed. Reg. 25,110, 25,114 (May 13, 1994) (appearing in a section titled “Manufacturer's Contracts Regarding 340B Compliance.”).

7. *Id.*

support manufacturer demands for data that CEs may share with payers or other third parties pursuant to entirely different business relationships that were established over decades.

Congress has consistently supported the integrity of the 340B program and its role in strengthening the health care safety net. Allowing manufacturers to condition statutory discounts on compliance with unilateral reporting requirements risks establishing a precedent that could fundamentally alter the operation of the program without congressional authorization.

Accordingly, we respectfully request that HRSA and HHS take immediate action to reinstate covered entities' uninterrupted access to 340B pricing for eligible drugs and use all available enforcement authorities to ensure manufacturers comply with their obligations under Section 340B of the Public Health Service Act. HRSA and HHS should clarify that manufacturers may not threaten access to 340B pricing based on the submission of claims data or other requirements not expressly authorized by statute.

The 340B program remains a critical tool for supporting hospitals, health centers, and other providers that serve vulnerable populations. We appreciate your prompt attention to this matter and look forward to your response.


Sincerely,



Doris Matsui  
Member of Congress



Jack Bergman  
Member of Congress



Mark Pocan  
Member of Congress



Stephanie Bice  
Member of Congress



Chris Pappas  
Member of Congress



Sharice L. Davids  
Member of Congress




Joseph D. Morelle  
Member of Congress




James P. McGovern  
Member of Congress



Valerie P. Foushee  
Member of Congress



Harold Rogers  
Member of Congress




John Garamendi  
Member of Congress




Debbie Dingell  
Member of Congress



Terri A. Sewell  
Member of Congress



Emanuel Cleaver, II  
Member of Congress



Jan Schakowsky  
Member of Congress




Adriano Espaillat  
Member of Congress



Shri Thanedar  
Member of Congress



Mike Quigley  
Member of Congress



Gabe Vasquez  
Member of Congress



Eleanor Holmes Norton  
Member of Congress



Derrick Van Orden  
Member of Congress



Suzan K. DelBene  
Member of Congress



Donald Norcross  
Member of Congress




Mike Thompson  
Member of Congress



SETH MOULTON  
Member of Congress




Marcy Kaptur  
Member of Congress



John W. Mannion  
Member of Congress



Dan Meuser  
Member of Congress




Jonathan L. Jackson  
Member of Congress




Gwen S. Moore  
Member of Congress



Rob Bresnahan, Jr.  
Member of Congress



Maggie Goodlander  
Member of Congress



Ritchie Torres  
Member of Congress




Salud Carbajal  
Member of Congress



Chellie Pingree  
Member of Congress




Michael K. Simpson  
Member of Congress




Gilbert Ray Cisneros, Jr.  
Member of Congress



Lori Trahan  
Member of Congress




Jefferson Van Drew  
Member of Congress




Hillary P. Scholten  
Member of Congress



Dan Goldman  
Member of Congress



Yvette D. Clarke  
Member of Congress



Kathy Castor  
Member of Congress




Haley M. Stevens  
Member of Congress




Stephen F. Lynch  
Member of Congress





Tracey Mann  
Member of Congress


  
Eric Sorensen  
Member of Congress


  
Alma S. Adams, Ph.D.  
Member of Congress

  
George Latimer  
Member of Congress


  
Gregory W. Meeks  
Member of Congress


  
Paul D. Tonko  
Member of Congress


  
Nikema Williams  
Member of Congress


  
Ayanna Pressley  
Member of Congress


  
Josh Riley  
Member of Congress


  
Madeleine Dean  
Member of Congress

  
Raja Krishnamoorthi  
Member of Congress

  
Thomas R. Suozzi  
Member of Congress


  
Emily Randall  
Member of Congress

  
Andrew R. Garbarino  
Member of Congress

  
Mark DeSaulnier  
Member of Congress




Danny K. Davis  
Member of Congress



Steve Cohen  
Member of Congress



Mary Gay Scanlon  
Member of Congress



Dwight Evans  
Member of Congress




Jim Tokuda  
Member of Congress



Julie Johnson  
Member of Congress



Jim Costa  
Member of Congress



Ferrol Nadler  
Member of Congress




Randy Beestra  
Member of Congress



Chris Deluzio  
Member of Congress



Teresa Leger Fernandez  
Member of Congress



Robin L. Kelly  
Member of Congress

